COMMUNIQUÉS West-GlobeNewswire

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
18/03/2024
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company [...]
Homology Medicines Declares Distribution to Common Stockholders
18/03/2024
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, [...]
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
18/03/2024
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat [...]
OBI Pharma annonce des présentations par affiches à la réunion annuelle de l’AACR 2024 pour OBI-992 et la plateforme CAM GlycOBI™
18/03/2024
Présentations par affiches pour mettre en lumière les dernières recherches sur OBI-992 (conjugué anticorps-médicament anti-TROP2) et la nouvelle plateforme de conjugué anticorps-médicament GlycOBI d’OBI TAIPEI, Taïwan, [...]
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18/03/2024
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy [...]
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
18/03/2024
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million [...]
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements
18/03/2024
Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB [...]
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
18/03/2024
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in [...]
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
18/03/2024
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to MicroPine for [...]
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
18/03/2024
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
18/03/2024
BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating [...]
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
18/03/2024
Initiated limited U.S. commercial launch of the Pure-Vu ® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systems The Company is engaged in the process to seek [...]
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
18/03/2024
The study, published in the journal Molecular Psychiatry , suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog Benefits are thought to include a more potent and [...]
Madrigal Pharmaceuticals Announces Proposed Public Offering
18/03/2024
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024
18/03/2024
ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5- [...]
Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023
18/03/2024
SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three and 12 months ended December 31 [...]
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
18/03/2024
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) i n heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late- [...]
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
18/03/2024
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. Statistical significance was also [...]
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2
18/03/2024
LEGEND a atteint son critère principal d’efficacité en réduisant de manière significative le taux d’hémoglobine HbA1c dans les groupes recevant lanifibranor seul ou en combinaison avec empagliflozine, par rapport au [...]

Pages